- Home
- IAE vs GANX Comparison
IAE vs GANX Comparison
Compare IAE & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | GANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 78.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IAE | GANX |
|---|---|---|
| Price | $7.88 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 37.8K | ★ 684.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.41 |
| 52 Week High | $8.30 | $4.34 |
Technical Indicators
Market Signals| Indicator | IAE | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 53.18 |
| Support Level | $7.85 | $1.55 |
| Resistance Level | $7.94 | $2.40 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 86.73 | 88.37 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.